TREM-1 Inhibitor Specificity and Timing of Treatment Initiation Can Impact Its Therapeutic Efficacy in Cancer and Inflammatory Disease

SignaBlok > News

SignaBlok > News

TREM-1 Inhibitor Specificity and Timing of Treatment Initiation Can Impact Its Therapeutic Efficacy in Cancer and Inflammatory Disease

Sigalov AB. Front Oncol. 2025

SignaBlok to present novel approach to preventing cancer recurrence at the 2026 American Association for Cancer Research (AACR) annual meeting

SignaBlok to present favorable preclinical data on a first-in-class TREM-1 therapy for retinopathy of prematurity (ROP) at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting

FDA grants Orphan Drug Designation to SignaBlok’s therapy for retinopathy of prematurity (ROP)

SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop TREM-1 therapy for the treatment of empyema

SignaBlok, in collaboration with the University of Texas at Tyler, awarded NHLBI / NIH CATALYZE grant to develop a novel treatment for pleural infection (empyema)

Inhibiting Triggering Receptor Expressed on Myeloid Cells 1 Signaling to Ameliorate Skin Fibrosis

Bale et al. JCI Insight. 2024

TREM-1 and TREM-2 as Therapeutic Targets: Clinical Challenges and Perspectives

Sigalov AB. Front Immunol. 2024

SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of sepsis, pulmonary inflammation and fibrosis at the 2025 Respiratory Innovation Summit (RIS) and American Thoracic Society (ATS) International Conference

SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting